DYN
Dyne Therapeutics Inc
16.00$
-2.9%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +2.7% | +13.1% | -9.8% | -99.9% | +98.8% | +2,049.8% | +20.5% | -28.0% | -46.1% | +318.7% | +71.7% | |
| – | -27.3% | +53.6% | -49.0% | -99.5% | +80.9% | +2,265.2% | +9.5% | -30.5% | -51.3% | +409.6% | +70.9% | |
| – | -73.0% | +251.7% | -79.4% | -97.8% | +80.1% | +1,956.1% | -33.2% | -14.3% | -29.3% | +258.0% | +105.2% | |
| – | -68.9% | +215.0% | -79.2% | -98.0% | +80.1% | +2,260.0% | +9.1% | -32.0% | -51.9% | +421.7% | +72.9% | |
| – | +48.9% | -4.0% | +32.9% | – | – | – | – | – | – | – | – | |
| – | +187.0% | -25.5% | +0.0% | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | +1,250.9% | +31.0% | +2,004.8% | -6.2% | – | – | – | |
| – | – | +0.3% | -3.4% | – | – | – | – | – | – | – | – | |
| – | +277.8% | -62.7% | -34.2% | – | – | – | – | – | – | – | – | |
| – | +5.0% | +27.8% | -10.4% | -99.9% | -81.7% | +357.0% | +424.0% | -6.1% | +36.7% | -16.8% | +249.9% | |
| – | +19.2% | +12.8% | +14.5% | -99.9% | +231.6% | +365.1% | +161.9% | -2.2% | +81.9% | -17.3% | +19.8% | |
| – | +167.7% | +142.2% | -47.8% | – | – | – | – | +18.4% | +2.4% | +2.8% | +3.0% | |
| – | +35.2% | +13.7% | +10.5% | -99.9% | +142.5% | +173.9% | +17.2% | +30.5% | +336.1% | -71.4% | +23.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -3.4% | -30.1% | -6.9% | -100.3% | – | +2,339.2% | +7.5% | -31.5% | -63.8% | +589.9% | +54.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +2.4% | +25.6% | -93.6% | +339.9% | +4.1% | +7.7% | +2.1% | +14.8% | +57.7% | +36.4% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.